Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
KUAISHOU-W
01024
5
JD HEALTH
06618
| (Q2)Sep 30, 2025 | (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q4)Mar 31, 2025 | (Q3)Dec 31, 2024 | (Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow (Indirect Method) | ||||||||||
| Cash from operating activities | 34.76%2.17M | 126.51%2.83M | -454.40%-15.19M | 40.81%2.04M | -749.88%-8.17M | 156.53%1.61M | -1,224.00%-10.68M | 563.90%4.29M | 2,644.46%1.45M | 125.19%1.26M |
| Net profit before non-cash adjustment | 75.25%1.61M | 2.54%1.45M | 8.94%3.6M | 11.24%753.6K | -55.96%510K | 17.56%917K | 106.57%1.42M | 70.57%3.3M | 887.39%677.43K | 11.99%1.16M |
| Total adjustment of non-cash items | -22.60%161K | 44.04%278K | 337.77%2.03M | 491.52%855.93K | 282.67%773K | 440.98%208K | 8.43%193K | -57.68%463.7K | -62.77%144.7K | -20.78%202K |
| -Depreciation and amortization | -6.25%180K | -11.63%190K | -14.79%769.95K | -30.11%156.95K | -9.25%206K | -13.51%192K | -6.52%215K | -8.56%903.57K | 3.41%224.57K | -10.98%227K |
| -Reversal of impairment losses recognized in profit and loss | ---- | ---- | 60,101,900.00%601.02K | 15,001,900.00%150.02K | 111.74%451K | --0 | --0 | 100.00%1 | -100.00%1 | 138.73%213K |
| -Assets reserve and write-off | ---- | ---- | 1,904.36%477.26K | ---- | ---- | ---- | ---- | -3.26%23.81K | ---- | ---- |
| -Disposal profit | --0 | --0 | 135.34%37.78K | -312.75%-217 | --0 | --38K | --0 | -128.76%-106.9K | 100.04%102 | -152.81%-320K |
| -Net exchange gains and losses | --1K | --99K | 200.58%214.72K | 228.27%82.72K | 116.39%132K | --0 | --0 | -184.74%-213.49K | -1,744.71%-64.49K | -41.35%61K |
| -Other non-cash items | 9.09%-20K | 50.00%-11K | 50.59%-70.8K | 72.51%-10.8K | -176.19%-16K | 69.86%-22K | 57.69%-22K | 26.38%-143.3K | -122.67%-39.3K | 113.13%21K |
| Changes in working capital | -17.08%403K | 108.97%1.1M | -4,083.88%-20.82M | -30.97%434.59K | -9,076.70%-9.45M | 634.07%486K | -14,221.84%-12.29M | 113.21%522.54K | 275.04%629.54K | 98.36%-103K |
| -Change in receivables | -58.99%399K | 111.34%1.37M | -16,937.26%-20.43M | -16.37%672.66K | -2,750.00%-10.03M | 620.32%973K | -8,264.58%-12.05M | 103.17%121.35K | 155.54%804.35K | 83.91%-352K |
| -Change in inventory | -206.25%-49K | 96.44%-33K | -459.60%-761.7K | 179.38%83.3K | 204.30%97K | -107.69%-16K | -1,482.09%-926K | -44.87%211.82K | -81.84%29.82K | -164.14%-93K |
| -Change in payables | 111.25%53K | -133.72%-231K | 98.35%375.63K | -57.06%-321.37K | 41.23%483K | -320.54%-471K | 317.68%685K | 136.80%189.38K | -122.14%-204.62K | 108.07%342K |
| Dividends paid (cash flow from operating activities) | ||||||||||
| Dividends received (cash flow from operating activities) | ||||||||||
| Interest paid (cash flow from operating activities) | ||||||||||
| Interest received (cash flow from operating activities) | ||||||||||
| Tax refund paid | -48.84%-448K | -352.54%-267K | -99.80%-1.47M | -51.05%-711.08K | -293.07%-397K | -281.01%-301K | 29.76%-59K | -66.41%-734.76K | -392.79%-470.76K | 34.84%-101K |
| Other operating cash inflow (outflow) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating cash flow | 31.53%1.72M | 123.88%2.56M | -569.04%-16.66M | 35.90%1.33M | -841.00%-8.57M | 138.62%1.31M | -1,339.84%-10.74M | 360.10%3.55M | 742.88%980.91K | 122.47%1.16M |
| Investing cash flow | ||||||||||
| Net PPE purchase and sale | 44.68%-26K | -33.33%-4K | 61.18%-237.54K | 13.49%-149.54K | 90.43%-38K | 98.61%-47K | -100.09%-3K | -129.57%-611.85K | -11,271.71%-172.85K | -1,317.86%-397K |
| Net business purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Interest received (cash flow from investment activities) | -23.08%20K | -52.17%11K | -52.81%78.05K | -69.21%13.05K | 184.21%16K | -65.33%26K | -65.67%23K | -66.21%165.39K | -34.24%42.39K | -110.50%-19K |
| Net changes in other investments | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 192.47%3.34M | --54 | --0 |
| Investing cash flow | 71.43%-6K | -65.00%7K | -105.52%-159.48K | -4.66%-136.48K | 94.71%-22K | -155.26%-21K | -99.41%20K | 375.16%2.89M | 96.94%-130.41K | -112.99%-416K |
| Financing cash flow | ||||||||||
| Net issuance payments of debt | --0 | --0 | 94.30%-87.67K | 110.49%335 | -1,900.00%-80K | -33.33%-4K | 99.74%-4K | -412.61%-1.54M | 95.62%-3.19K | 94.59%-4K |
| Net common stock issuance | --3.18M | --3.41M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Interest paid (cash flow from financing activities) | --0 | --0 | 67.18%-7.25K | 27.27%-2.25K | --0 | -100.00%-4K | 93.33%-1K | 72.97%-22.1K | 87.50%-3.1K | 90.48%-2K |
| Financing cash flow | 39,825.00%3.18M | 68,340.00%3.41M | 93.91%-94.92K | 69.53%-1.92K | -1,233.33%-80K | -60.00%-8K | 99.68%-5K | -308.59%-1.56M | 93.56%-6.29K | 93.68%-6K |
| Net cash flow | ||||||||||
| Beginning cash position | -3.19%15.89M | -63.12%10.01M | 23.13%27.14M | -66.09%8.9M | -30.76%17.7M | -33.72%16.41M | 23.13%27.14M | -12.16%22.04M | -1.22%26.23M | -10.94%25.56M |
| Current changes in cash | 282.12%4.9M | 155.80%5.98M | -446.31%-16.91M | 41.51%1.19M | -1,280.93%-8.67M | 120.10%1.28M | -493.61%-10.72M | 274.56%4.88M | 118.71%844.21K | 136.03%734K |
| Effect of exchange rate changes | ---1K | ---99K | -200.58%-214.72K | -228.27%-82.72K | -116.39%-132K | --0 | --0 | 184.74%213.49K | 1,744.71%64.49K | 41.35%-61K |
| End cash Position | 17.46%20.79M | -3.19%15.89M | -63.12%10.01M | -63.12%10.01M | -66.09%8.9M | -30.76%17.7M | -33.72%16.41M | 23.13%27.14M | 23.13%27.14M | -1.22%26.23M |
| Free cash flow | 61.16%1.7M | 123.84%2.56M | -704.71%-17.11M | 46.64%1.18M | -1,425.73%-8.6M | 105.66%1.05M | -1,347.39%-10.74M | 273.22%2.83M | 619.87%807.06K | 112.55%649K |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.